NFkB Luciferase Reporter Jurkat Stable Cell Line is derived from human T lymphocyte cells, and stably express firefly luciferase reporter gene under the control of the NF-kB response enhancer element. This cell line is an ideal cellular model for monitoring the activation of NFkB pathway triggered by stimuli treatment, enforced gene expression and gene knockdown. This cell line express CD3 and CD28 (see data below).
 
NF-κB is a critical regulator of inflammatory responses, proliferation and differentiation of T-cells. The aberrant activation of NFkB can contribute to the development of autoimmunity, chronic inflammation, or lymphoid cancer. Jurkat cells are human T lymphocyte cells widely used to study T cell signaling.
 
Signosis developed a stable Jurkat NFkB-luciferase reporter stable cell line, which can be used for easily monitoring the activation of NFkB activation in T cells through sensitive luciferase analysis. This cell line was established by transfection using a pTA-NFkB-luciferase reporter vector, along with hygromycin expression vector followed by hygromycin selection. The hygromycin resistant clones were subsequently screened for luciferase activity induced by TNFapha treatment.
 
Principle behind TF luciferase reporter. TF luciferase reporter stable cell line utilizes artificial promoter constructs to drive luciferase expression. The promoter region can consists of multiple repeats of a cis-element TF binding site, a DNA fragment from the promoter region of a known TF downstream gene, or a DNA fragment containing putative/known TF binding sites. There are several ways that a TF can be activated, such as through extracellular stimuli or through intracellular signaling pathways. Once activated, the TF translocates to the nucleus and often interacts with relevant co-factors to drive gene expression. Once luciferase is expressed, it can generate light in an enzymatic assay and the amount of light measured is positively correlated with the level of TF activation.